In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
|Videos|June 25, 2021
Dr. Eure on clinical use and reimbursement of UroLift for BPH
Author(s)Urology Times staff
Advertisement
Gregg Eure, MD, FACS, Urology of Virginia, discusses the UroLift System as an early, noninvasive treatment option for patients with BPH. He also addresses reimbursement of the treatment.
Advertisement
Related to this article
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5